Novel therapies for cutaneous T-cell lymphoma: What does the future hold?

Expert Opinion on Investigational Drugs

Volumn 23, Issue 4, 2014, Pages 457-467

  Guenova, Emmanuella ^a   Hoetzenecker, Wolfram ^a   Rozati, Sima ^a   Levesque, Mitchell P ^a   Dummer, Reinhard ^a   Cozzio, Antonio ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Alemtuzumab; Brentuximab; Cutaneous lymphoma; Mycosis fungoides; Panobinostat; Pralatrexate; Sezary syndrome; Th1; Th2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALEMTUZUMAB; ANTHRACYCLINE; ANTIBIOTIC AGENT; ARSENIC TRIOXIDE; AZACITIDINE; BEXAROTENE; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CD30 ANTIGEN; CD52 ANTIGEN; CHEMOKINE RECEPTOR CCR4; DEXAMETHASONE; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 31 ANTIBODY; IPILIMUMAB; LENALIDOMIDE; METHOTREXATE; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PANOBINOSTAT; PRALATREXATE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; RETINOID; ROMIDEPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ZANOLIMUMAB;

ANTIANGIOGENIC ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ASTHMA; AUTOPHAGY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL CYCLE ARREST; CELL MEDIATED CYTOTOXICITY; CHEMORADIOTHERAPY; CUTANEOUS T CELL LYMPHOMA; DENDRITIC CELL; DNA METHYLATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; EVIDENCE BASED MEDICINE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; LYMPHOPROLIFERATIVE DISEASE; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MYCOSIS FUNGOIDES; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SKIN LYMPHOMA; STEM CELL TRANSPLANTATION; SUBCUTANEOUS T CELL LYMPHOMA; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; SKIN NEOPLASMS;

EID: 84896128144     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.876407     Document Type: Review

References (91)

1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004;350(19):1978-88 . (Pubitemid 38580201)
2. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005;115(4):798-812 . (Pubitemid 40489380)
3. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006;42(8):1014-30
4. Wong HK, Mishra A, Hake T, et al. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155(2):150-66
5. DeSimone JA, Guenova E, Carter JB, et al. Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2013;69(1):61-5
6. Dummer R, Goldinger SM, Cozzio A, et al. Cutaneous lymphomas: molecular pathways leading to new drugs. J Invest Dermatol 2012;132(3 Pt 1):517-25
7. Zinzani PL, Corradini P, Gallamini A, et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012;53(5):789-95
8. Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655-62 . (Pubitemid 46827755)
9. Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28(11):1870-7
10. Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50(12):1969-76
11. Campbell JJ, Clark RA, Watanabe R, et al. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010;116(5):767-71
12. Clark RA, Watanabe R, Teague JE, et al. Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. Sci Transl Med 2012;4(117):117ra7
13. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti- CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101(11):4267-72 (Pubitemid 36857787)
14. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and sezary syndrome with alemtuzumab. Eur J Haematol 2003;71(4):250-6 (Pubitemid 37174695)
15. Faguer S, Launay F, Ysebaert L, et al. Acute cutaneous T-cell lymphoma transformation during treatment with alemtuzumab. Br J Dermatol 2007;157(4):841-2 (Pubitemid 47389908)
16. Fernandes IC, Goncalves M, Teixeira MD, et al. Can the level of CD52 expression on sezary cells be used to predict the response of sezary syndrome to alemtuzumab? J Am Acad Dermatol 2012;67(5):1083-5 .
17. Smith CA, Gruss HJ, Davis T, et al. CD30 antigen, a marker for Hodgkin?s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73(7):1349-60 (Pubitemid 23201148)
18. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin?s disease and a subset of normal lymphoid cells. Nature 1982;299(5878):65-7 (Pubitemid 12049770)
19. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin?s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66(4):848-58 (Pubitemid 15242469)
20. Romagnani P, Annunziato F, Manetti R, et al. High CD30 ligand expression by epithelial cells and Hassal?s corpuscles in the medulla of human thymus. Blood 1998;91(9):3323-32 (Pubitemid 28193883)
21. Chiarle R, Podda A, Prolla G, et al. CD30 in normal and neoplastic cells. Clin Immunol 1999;90(2):157-64 (Pubitemid 29162160)
22. Deng C, Pan B, O?Connor OA. Brentuximab vedotin. Clin Cancer Res 2013;19(1):22-7 .
23. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105(10):3768-85 (Pubitemid 40656118)
24. Duvic M, Tetzlaff H, Gangar P, et al. Phase II trial of brentuximab vedotin (SGN-35) for CD30+ cutaneous T-cell lymphomas and lymphoproliferative disorders. J Invest Dermatol 2013;133:S180 .
25. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol 2009;129(5):1115-19
26. Subramaniam JM, Whiteside G, McKeage K, et al. Mogamulizumab: first global approval. Drugs 2012;72(9):1293-8 .
27. Available from: http://www.clinicaltrials. gov/ct2/results?term= Mogamulizumab
28. Han T, Abdel-Motal UM, Chang DK, et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS One 2012;7(9):e44455
29. O?Connor OA, Horwitz S, Hamlin P, et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol 2009;27(26):4357-64 .
30. Sirotnak FM, DeGraw JI, Colwell WT, et al. A new analogue of 10- deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 1998;42(4):313-18 (Pubitemid 28393849)
31. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119(18):4115-22
32. Chen L, Wang J, Hu X, et al. Meta-analysis of all-trans retinoic acidlinked arsenic trioxide treatment for acute promyelocytic leukemia. Hematology 2013. [Epub ahead of print]
33. Tun-Kyi A, Qin JZ, Oberholzer PA, et al. Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. Ann Oncol 2008;19(8):1488-94
34. Kelly-Sell MJ, Kim YH, Straus S, et al. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol 2012;87(4): 354-60
35. Song W, Tai YT, Tian Z, et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011;25(1):161-8
36. Kim YH, Demierre MF, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma 2013;54(2):284-9 .
37. Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28(29):4485-91
38. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27(32):5410-17
39. Ellis L, Pan Y, Smyth G, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008;14(14):4500-10
40. Duvic M, Dummer R, Becker J, et al. Panobinostat activity in both bexaroteneexposed and -nai?ve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 2013;49(2):386-94
41. Khot A, Dickinson M, Prince HM. Panobinostat in lymphoid and myeloid malignancies. Expert Opin Investig Drugs 2013;22(9):1211-23
42. Reddy P, Zou W. Blocking HDACs boosts regulatory T cells. Nat Med 2007;13(11):1282-4 (Pubitemid 350073584)
43. Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21(1):103-7 (Pubitemid 29036293)
44. Available from: http://clinicaltrials.gov/ ct2/results?term= carfilzomib+and +romidepsin
45. Available from: http://clinicaltrials.gov/ ct2/show/NCT00972842? term=lenalidomid&rank=3
46. Dummer R, Rozati S, Guenova E, et al. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. Future Oncol 2013;9(8):1061-4
47. Samimi S, Morrissey K, Anshelevich S, et al. Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma. J Am Acad Dermatol 2013;68(1):e5-6
48. Gardner JM, Evans KG, Musiek A, et al. Update on treatment of cutaneous T-cell lymphoma. Curr Opin Oncol 2009;21(2):131-7
49. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs 2010;70(3):273-86
50. Raaijmakers MI, Rozati S, Goldinger SM, et al. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 2013;5(2):169-82
51. Weber JS, O?Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008;26(36):5950-6
52. Gibson HM, Mishra A, Chan DV, et al. Impaired proteasome function activates GATA3 in T cells and upregulates CTLA-4: relevance for Sezary syndrome. J Invest Dermatol 2013;133(1):249-57
53. Wong HK, Wilson AJ, Gibson HM, et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides - cutaneous T cell lymphoma. J Invest Dermatol 2006;126(1):212-19 . (Pubitemid 43336115)
54. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
55. Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer - response. Clin Cancer Res 2013; 19(19):5542
56. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
57. Kantekure K, Yang YS, Raghunath P, et al. Expression patterns of the immunosuppressive proteins PD-1/ CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/ mycosis fungoides. Am J Dermatopathol 2012;34(1):126-8 .
58. Cetinozman F, Jansen PM, Vermeer MH, et al. Differential expression of programmed death-1 (PD-1) in sezary syndrome and mycosis fungoides. Arch Dermatol 2012;148(12):1379-85
59. McKenzie RCT, Jones CL, Tosi I, et al. Constitutive activation of STAT3 in sezary syndrome is independent of SHP-1. Leukemia 2012;26(2):323-31
60. van der Fits L, Out-Luiting JJ, van Leeuwen MA, et al. Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in sezary syndrome. J Invest Dermatol 2012; 132(2):440-7
61. Page BDG, Ball DP, Gunning PT. Signal transducer and activator of transcription 3 inhibitors: a patent review. Expert Opin Ther Pat 2011;21(1):65-83
62. Dobbeling U, Waeckerle-Men Y, Zabel F, et al. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Exp Dermatol 2013;22(2):119-24
63. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9(5):997-1010
64. Rook AH, Vowels BR, Jaworsky C, et al. The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by sezary T cells. Arch Dermatol 1993;129(4):486-9 (Pubitemid 23118249)
65. Tendler CL, Burton JD, Jaffe J, et al. Abnormal cytokine expression in sezary and adult T-cell leukemia cells correlates with the functional diversity between these T-cell malignancies. Cancer Res 1994;54(16):4430-5
66. Guenova E, Watanabe R, Teague JE, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 2013;19(14):3755-63
67. Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370(9596):1422-31 (Pubitemid 47576168)
68. Guenova E, Volz T, Sauer K, et al. IL-4-mediated fine tuning of IL-12p70 production by human DC. Eur J Immunol 2008;38(11):3138-49
69. Sokolowska-Wojdylo M, Glen J, Zablotna M, et al. Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis. J Eur Acad Dermatol Venereol 2013;27(5):662-4
70. Hartmann K, Wagner N, Rabenhorst A, et al. Serum levels of IL-31 are increased in mastocytosis and correlate with disease severity in adult patients. Exp Dermatol 2013;22(3):E2
71. Singer EM, Nattkemper LA, Benoit BM, et al. IL-31 is produced by the malignant T cell population in cutaneous T-cell lymphoma and its expression correlates with pruritus. J Invest Dermatol 2013;133:S159.
72. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005;141(3):305-11 (Pubitemid 40365446)
73. Guitart J, Wickless SC, Oyama Y, et al. Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 2002;138(10):1359-65
74. Kiessling MK, Oberholzer PA, Mondal C, et al. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011;117(8):2433-40
75. Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18(2):555-67
76. Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a nonrandomised, open-label phase 2 study. Lancet Oncol 2013;14(3):249-56
77. Thomas ED, Lochte HL Jr, Lu WC, et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med 1957;257(11):491-6
78. Hahn T, McCarthy PL Jr, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013;31(19):2437-49
79. Dummer R, Quaglino P, Becker JC, et al. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012;30(33):4091-7
80. Horwitz SM, Olsen EA, Duvic M, et al. Review of the treatment of mycosis fungoides and sezary syndrome: a stagebased approach. J Natl Compr Cancer Netw 2008;6(4):436-42 (Pubitemid 351642616)
81. Koeppel MC, Stoppa AM, Resbeut M, et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta Derm Venereol 1994;74(4):331-2 (Pubitemid 24243864)
82. Schlaak M, Pickenhain J, Theurich S, et al. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2012;1:CD008908
83. Schlaak M, Pickenhain J, Theurich S, et al. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;8:CD008908
84. Schlaak M, Theurich S, Pickenhain J, et al. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: a systematic review. Crit Rev Oncol Hematol 2013;85(1):21-31
85. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous Tcell lymphoma. Bone Marrow Transplant 2008;41(7):597-604 (Pubitemid 351523997)
86. Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28(29):4492-9
87. Gopal AK, Ramchandren R, O?Connor OA, et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012;120(3):560-8
88. Quintanilla-Martinez L, Jansen PM, Kinney MC, et al. Non-mycosis fungoides cutaneous T-cell lymphomas: report of the 2011 Society for Hematopathology/ European Association for Haematopathology workshop. Am J Clin Pathol 2013;139(4):491-514
89. Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008;111(2):838-45
90. Bashey S, Krathen M, Abdulla F, et al. Romidepsin is effective in subcutaneous panniculitis-like T-cell lymphoma. J Clin Oncol 2012;30(24):e221-5
91. Zhang X, Schlaak M, Fabri M, et al. Successful treatment of a panniculitislike primary cutaneous T-cell lymphoma of the alpha/beta type with bexarotene. Case Rep Dermatol 2012;4(1):56-60